COMP <GO>
TXG vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
10x Genomics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: TXG 3
— LLY 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $81.55 (-2.47%) • MKT CAP: $10.63B
roic
-5.70%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 83.64% | -14.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -5.70% | 32.36% | -38.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 2.30% | -1.08 | LLY | /fcf-yield <GO> |
| Operating Margin | -9.50% | 40.21% | -49.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | -6.80% | 31.90% | -38.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 45.51% | -40.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 9.29 | +15.73 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.0 | 66.6 | -11.60 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.51 | +0.64 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 26.3x | -2.25 | TXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.63B | $1.29T | -$1.28T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | LLY REV | TXG GROSS % | LLY GROSS % | TXG FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $65.18B | 69.1% | 83.0% | $130.1M | $16.81B |
| FY 2024 | $610.8M | $45.04B | 67.9% | 81.3% | -$5.7M | $8.82B |
| FY 2023 | $618.7M | $34.12B | — | 79.3% | -$43.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
LLY // BETA 0.51